|
|
|
|
|
|
- Fibrogen veteran brings global R&D expertise to Management Team
- Merck KGaA Executive Sophie (Zhengjie) Sun named Senior Vice President, Corporate Development bringing partnership, strategy and commercialization expertise |
Foster City, CA, and Hangzhou, China, Mar 9, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of K. Peony Yu, M.D. as Chief Medical Officer. Dr. Yu will assume the role on March 16, 2021. Apollomics also announced that Sophie (Zhengjie) Sun has been named as Senior Vice President, Corporate Development and will be based in the Company's China office. Both executives report to Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of the Company.
"Dr. Yu joins us with an incredible leadership and global drug development background that is a perfect fit for Apollomics, and we are thrilled to welcome her to our team," said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "Peony's extensive cross border experience includes managing teams in both the U.S. and China and overseeing multiple functions including clinical development, regulatory strategy and medical affairs. Peony will be instrumental in our efforts to advance our current assets and expand our development pipeline."
"Apollomics patient centric focus aligns with my priorities and I am excited to join the team. The Company's precision medicine approach targeting specific mutations, amplifications and resistance mechanisms is technology that I believe can make a difference and bring transformative therapies to cancer patients. I look forward to contributing to this effort and advancing the clinical development programs globally," added K. Peony Yu, M.D.
Dr. Guo-Liang Yu, concluded, "Since inception, Apollomics has built numerous partnerships and we continuously explore options to broaden our portfolio. We are excited to welcome Sophie Sun who will be responsible for corporate strategy, business development, and strategic collaboration. Her diversified career covers three continents and her leadership in strategy, partnering, and commercialization will be a valuable resource as we continue our fight against cancer."
K. Peony Yu, M.D.
Dr. Yu spent 12 years at Fibrogen where she served in multiple roles of increasing responsibility culminating in her appointment as Chief Medical Officer in 2016. She brings leadership and expertise in design and execution of clinical development programs in all phases of development, including clinical and regulatory strategy, and interactions with global regulatory authorities.. Prior to joining Fibrogen, Dr. Yu was Vice President and Head of Clinical Research at Anesiva, Inc. (formerly known as Corgentech, Inc., (NASDAQ: ANSV)), where she was responsible for management of clinical research, statistics/data management, clinical operations, and medical affairs/medical information for all clinical programs. Dr. Yu received a Doctor of Medicine degree from the University of California, Davis. She completed her residency training at Stanford Medical School.
Sophie (Zhengjie) Sun, MBA
Sophie Sun joins Apollomics from Merck KGaA, where she was most recently Vice President & Managing Director, Innovation Hubs China. In this role, Ms. Sun oversaw Merck KGaA's development partnerships in China for China and global markets. She was with Merck KGaA for twelve years holding multiple roles of increasing responsibility including participation in nine new product launches. Prior to Merck KGaA, Ms. Sun spent over eight years at marketing agencies Interpublic Group (IPG) and WPP, where she consulted for many Fortune 500 companies covering a wide range of industries. Ms. Sun received a Master's degree from Remin University of China, and a Master of Business Administration from MIT Sloan School of Management.
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.apollomicsinc.com.
Contact Information:
Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com
U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com
China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com
Phoenix Fung
Assistant Vice President
(852) 3150 6773
phoenix.fung@pordahavas.com
Topic: Press release summary
Source: Apollomics, Inc.
Sectors: Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Apollomics, Inc. |
| Mar 30, 2023 20:29 HKT/SGT |
|
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq |
| July 26, 2022 09:17 HKT/SGT |
|
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer |
| Jan 12, 2022 09:25 HKT/SGT |
|
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 |
| Jan 4, 2022 10:10 HKT/SGT |
|
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group |
| Nov 22, 2021 10:40 HKT/SGT |
|
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia |
| Oct 1, 2021 10:00 HKT/SGT |
|
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial |
| Aug 10, 2021 11:53 HKT/SGT |
|
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102 |
| May 20, 2021 13:36 HKT/SGT |
|
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH |
| Mar 4, 2021 11:30 HKT/SGT |
|
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China |
| Feb 12, 2021 13:00 HKT/SGT |
|
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa |
| More news >> |
 |
|
|
|
